Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Human papillomavirus vaccines.

F Breitburd1, P Coursaget

  • 1Unite@a3 des Papillomavirus, Unite@a3 Mixte Institut Pasteur/INSERM U190, Institut Pasteur, 25 rue du Docteur Roux, Paris, 75015, France.

Seminars in Cancer Biology
|March 14, 2000
PubMed
Summary

Human papillomavirus (HPV) vaccines, including prophylactic and therapeutic types, are being developed to prevent and treat HPV infections and cervical cancer. Research focuses on novel vaccine designs and administration methods for broad protection.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Human papillomavirus (HPV) vaccines].

Virologie (Montrouge, France)·2021
Same author

Prognostic value of antibodies to Merkel cell polyomavirus T antigens and VP1 protein in patients with Merkel cell carcinoma.

The British journal of dermatology·2015
Same author

Screening of human papillomavirus infection in women with systemic sclerosis.

Clinical and experimental rheumatology·2014
Same author

Lipid nanocapsule functionalization by lipopeptides derived from human papillomavirus type-16 capsid for nucleic acid delivery into cancer cells.

International journal of pharmaceutics·2013
Same author

Vitamin D deficiency is associated with greater tumor size and poorer outcome in Merkel cell carcinoma patients.

Journal of the European Academy of Dermatology and Venereology : JEADV·2013
Same author

Identification of type-specific and cross-reactive neutralizing conformational epitopes on the major capsid protein of human papillomavirus type 31.

Archives of virology·2006

Area of Science:

  • Virology
  • Immunology
  • Oncology
  • Vaccinology

Background:

  • Genital human papillomavirus (HPV) infections are common sexually transmitted diseases causing condylomas and precancerous cervical lesions.
  • Current prophylactic vaccines target L1/L2 capsid proteins, inducing neutralizing antibodies for infection prevention.
  • Therapeutic vaccines aim to stimulate regression of existing lesions by targeting non-structural viral proteins.

Purpose of the Study:

  • To review the development and evaluation of prophylactic and therapeutic HPV vaccines.
  • To discuss ongoing clinical trials and future directions in HPV vaccine research.
  • To highlight the potential of HPV vaccines in preventing cervical carcinoma.

Main Methods:

  • Review of preclinical animal models and clinical trials (Phase I/II/III) for HPV vaccines.
  • Analysis of vaccine designs including virus-like particles (VLPs), chimeric proteins, and novel delivery systems.
  • Evaluation of endpoints for vaccine efficacy, such as viral DNA detection and lesion screening.

Main Results:

  • Prophylactic vaccines based on L1/L2 VLPs are in clinical trials for HPV6/11 and HPV16.
  • Second-generation vaccines incorporate structural and non-structural proteins to induce broader immunity.
  • Therapeutic vaccines targeting E6/E7 proteins are under investigation for advanced cervical cancer and high-grade lesions.

Conclusions:

  • HPV vaccines hold significant promise for preventing cervical carcinoma.
  • Ongoing research explores diverse vaccine platforms, valencies, and administration routes.
  • Community support and further clinical trials are crucial for the successful implementation of HPV vaccines.

Related Experiment Videos